# TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria

> **NCT05883176** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 35 (estimated)

## Conditions studied

- Hepatocellular Carcinoma by BCLC Stage

## Interventions

- **DRUG:** Bevacizumab Biosimilar QL 1101

## Key facts

- **NCT ID:** NCT05883176
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-07-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05883176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05883176, "TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05883176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*